The Muscular Dystrophy Association (MDA) held its first-ever Clays for a Cure event on Friday, Sept. 20. Check out the photos ...

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular ...

Duchenne muscular dystrophy, or DMD, is a severe genetic disorder, typically affecting males, and is characterized by progressive ...

Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...

Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...

Wave Life Sciences (WVE) stock rises on positive interim data from a Phase 2 trial for for WVE-N531, a therapy for Duchenne ...

Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing ...

Discover Avidity Biosciences' groundbreaking patent for treating facioscapulohumeral muscular dystrophy (FSHD) using a novel polynucleic acid conjugate targeting the DUX4 gene.

A mother and son from Georgia recently visited Kentucky for the first time. What drew them in, they say, was the ...

Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and a $59 price target, citing ...

The Lima Fire Department is saying thank you to those who donated to their "Fill the Boot" campaign back in August.